Announcement • Jun 11
Prescient Therapeutics Limited Announces Chief Medical Officer Changes Prescient Therapeutics Limited announced the appointment of Dr Rosalind Wilson as Chief Medical Officer (CMO) effective 13 July 2026. Dr Wilson is a highly accomplished pharmaceutical and biotechnology executive with more than 30 years' experience spanning clinical development, regulatory strategy and executive leadership. Her appointment further strengthens Prescient's leadership team as the Company advances its pipeline through key stages of clinical development. The Company's current CMO, Dr Marissa Lim, has decided to step-back from full-time employment and move into semi-retirement, following a significant contribution to the progression of Prescient's clinical programs. Dr Wilson has held senior global leadership roles including Global Head of Drug Development at Telix Pharmaceuticals, CEO of ASX-listed Factor Therapeutics, and has previously served as Chief Medical Officer for oncology-focused biotechnology companies. Earlier in her career, she led the global development and launch strategy for pertuzumab (Perjeta) at Roche, contributing to accelerating approval timelines and landmark regulatory precedents in breast cancer. Her experience spans the full drug development continuum - from Phase 1 studies through to regulatory submission and commercial launch - across multiple oncology indications. As CMO, Dr Wilson will lead Prescient's clinical development strategy and execution, including advancement of PTX-100 in its Phase 2 CTCL study and progression of the broader pipeline. New Risk • May 20
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 14% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 16% per year over the past 5 years. Shareholders have been substantially diluted in the past year (31% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (14% average weekly change). Revenue is less than US$5m (AU$4.3m revenue, or US$3.0m). Market cap is less than US$100m (AU$68.3m market cap, or US$48.7m). New Risk • Dec 24
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 14% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 17% per year over the past 5 years. Shareholders have been substantially diluted in the past year (31% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (14% average weekly change). Revenue is less than US$5m (AU$4.4m revenue, or US$2.9m). Market cap is less than US$100m (AU$89.4m market cap, or US$59.9m). 
